Galapagos NV
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
15 jun 2015 - 07:43
Statutaire naam
Galapagos NV
Titel
AbbVie and Galapagos present cystic fibrosis corrector and potentiator screening approach at ECFS conference
Bericht
Mechelen, Belgium; 15 June 2015 - Galapagos NV (Euronext & NASDAQ: GLPG) announced a joint presentation with AbbVie (NYSE: ABBV) at the 38th annual European Cystic Fibrosis Society conference in Brussels, Belgium.
"Development of Trafficking Assays to Evaluate Novel Corrector-Potentiator Combinations," presented by Dr Corina Balut of AbbVie, disclosed for the first time new assays developed by Galapagos and AbbVie to evaluate the impact of corrector molecules on the rescue of CFTR-F508del and to gain insight into the influence of each component in combination cocktails. Among these was the combination of AVI-tagged CFTR with an MSD discovery platform to provide a more specific and sensitive approach in studying the endocytosis and degradation rate of plasma membrane CFTR. This particular new assay also characterizes the effect of various correctors on channel stability at the cell surface and its endocytosis/recycling, allowing for a better understanding of the mechanism of action of compounds.
Datum laatste update: 19 december 2025